Forget Kalshi Bets: This Under-the-Radar Sports Data Stock Could Actually Mint Millionaires

Genius Sports is highlighted as a picks-and-shovels beneficiary of the growth in prediction markets and sports wagering, even as the stock is down more than 60% year to date and trades near $4.50. The company expects a potential post-merger lift from its planned $900 million acquisition of Legend, plus a $300 million earnout, which could raise adjusted EBITDA from $190 million to as much as $320 million and operating margin from 23% to 30%. Sell-side estimates now see earnings rising to $0.28 per share in 2027 and $0.60 in 2028, suggesting upside if the turnaround materializes.

Analysis

GENI looks less like a pure betting-beta name and more like a tollbooth on a structural increase in wagering surface area. The key second-order effect is that prediction markets don’t just create more volume; they increase the value of verified real-time sports data, which should widen the moat for whichever vendor is embedded in the stack before the trade happens. That matters because pricing power in this model is driven by switching costs and latency, not brand, so incremental product adoption can flow through at much higher margin than the market is currently underwriting.

The current setup is attractive because sentiment is still anchored to the prior drawdown while the business is moving into a more levered operating regime. Once a fixed-cost-heavy data platform gets to sustained adjusted EBITDA profitability, each additional contract win or media asset can re-rate the equity disproportionately, especially if the merger closes and cross-sell synergies land on time. The market is likely discounting execution risk on integration more than it is valuing the possibility that the combined asset mix shifts GENI from a “niche vendor” multiple toward a media/data infrastructure multiple.

The contrarian miss is that the real competition may not be Kalshi or Polymarket, but the large distribution owners who can internalize data and customer acquisition over time. DraftKings and Flutter can tolerate lower near-term economics to bundle prediction-market functionality into broader engagement funnels, which could cap GENI’s long-run take rate if the stack becomes commoditized. So the setup is bullish, but the duration of the moat is the key variable; this is a 6-18 month catalyst story, not a forever compounder call.

The main risk is that the stock can stay cheap if the market demands proof of merger integration before rerating, and any slip in close timing or synergy realization would extend the de-rating. On the other hand, if the merger closes cleanly and consensus EPS inflects over the next 2-3 reporting cycles, the stock could move much faster than fundamentals alone would suggest because positioning is likely still light.

Key Decisions for Investors

• Go long GENI on post-close confirmation or any earnings pullback; target a 6-12 month move as the market starts capitalizing EBITDA rather than sales, with upside skew if integration milestones are met.
• Buy GENI call spreads 6-12 months out to express the rerating thesis while capping downside from merger/execution slippage; favorable if implied vol remains depressed versus event risk.
• Pair long GENI / short DKNG for a 3-9 month relative-value trade: own the picks-and-shovels infra beneficiary while fading a business that may have to spend more to defend engagement if prediction markets scale.
• Avoid chasing FLUT or DKNG purely on prediction-market headlines until there is evidence of monetization; they may absorb more strategic optionality but also more competitive pressure and lower incremental margin.
• Set a catalyst watch on merger integration and next two earnings prints; if adjusted EBITDA margin fails to trend toward the implied post-deal range, reduce exposure quickly because the rerating thesis breaks.